Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.55 |
| ▸ | YAP1 | P46937 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | STS | P08842 | 1/20 | 0.50 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20660016 | 1.00 | GPR119 (0.55) | GPR119YAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3257929 | 1.00 | GPR119 (0.55) | GPR119YAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30700640 | 0.94 | GPR119 (0.53) | GPR119YAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22552461 | 0.93 | GPR119 (0.56) | GPR119YAP1STSSYKL3MBTL1 | |
| SCHEMBL21062628 | 0.93 | GPR119 (0.56) | GPR119YAP1STSSYKL3MBTL1 | |
| SCHEMBL22552460 | 0.93 | GPR119 (0.56) | GPR119YAP1STSSYKL3MBTL1 | |
| SCHEMBL15898105 | 0.90 | SYK (0.49) | GPR119YAP1SMN1; SMN2HTTSYK | |
| SCHEMBL25245210 | 0.88 | GPR119 (0.59) | GPR119YAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17591749 | 0.88 | GPR119 (0.59) | GPR119YAP1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3661565 | 0.88 | GPR119 (0.57) | GPR119YAP1NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-9796705-B2 | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2545060-B1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2015-11-25 | — | — | EP | disclosed |
| US-8980920-B2 | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8980920-B2 | Antiviral compounds of three linked aryl moieties to treat diseases such as hepatitis C | MERCK SHARP & DOHME CORP. (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2435424-B1 | ANTIVIRAL COMPOUNDS COMPOSED OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | MERCK SHARP & DOHME (US) | 2015-01-21 | — | — | EP | disclosed |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | Merck Sharp & Dohmn Corp. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20130164258-A1 | Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C | MERCK SHARP & DOHME LLC | 2013-06-27 | — | — | US | disclosed |
| US-20130164258-A1 | Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C | MERCK SHARP & DOHME LLC | 2013-06-27 | — | — | US | disclosed |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | SCHERING CORPORATION | 2013-06-20 | — | — | US | disclosed |
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | SCHERING CORPORATION (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012040924-A1 | FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012041227-A1 | TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| WO-2012040923-A1 | TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | NPPA, LNPEP, CLPP | GPR119 2001/4885YAP1 1942/4885NPC1 1580/4885 |
| US-20130156731-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEAS | HAVCR2, ELOC, ZC3HAV1 | GPR119 4361/4885YAP1 2756/4885NPC1 193/4885 |
| US-20120258078-A1 | ANTIVIRAL COMPOUNDS OF THREE LINKED ARYL MOIETIES TO TREAT DISEASES SUCH AS HEPATITIS C | HAVCR2, ZC3HAV1, EIF2AK2 | GPR119 1640/4885YAP1 3939/4885NPC1 74/4885 |
| US-20170008879-A1 | FUSED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | ZC3HAV1, HAVCR2, ZC3HAV1L | GPR119 4188/4885YAP1 3657/4885NPC1 39/4885 |
| US-20110223134-A1 | FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | FOXM1, ZC3HAV1L, C1S | GPR119 3054/4885YAP1 404/4885NPC1 16/4885 |
| US-20130164258-A1 | Antiviral Compounds Composed of Three Aligned Aryl Moieties to Treat Diseases such as Hepatitis C | HAVCR2, ZC3HAV1, EIF2AK2 | GPR119 1528/4885YAP1 3121/4885NPC1 62/4885 |
| US-20140170111-A1 | FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HAVCR2, ZC3HAV1, ZC3HAV1L | GPR119 1354/4885YAP1 2204/4885NPC1 288/4885 |
| US-11279735-B2 | Cyclic peptide antibiotics | NPPA, LNPEP, CLPP | GPR119 2001/4885YAP1 1942/4885NPC1 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.